Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ian Schofield

Edinburgh, U.K
Ian Schofield has been writing on issues affecting the pharmaceutical and biotech industry since the mid-1980s, specialising in EU and global policy and regulatory affairs.  As well as writing, editing and commissioning articles for Pharma Intelligence, Ian works for the Ask the Analyst service, providing tailor-made answers to questions posed directly by clients. He has a degree in modern languages from the University of Bath. Outside the realm of work, Ian plays guitar in a traditional music group and also enjoys a touch of cycling and gardening. He lives by the seaside about three miles from the centre of Edinburgh.
Set Alert for Articles By Ian Schofield

Latest From Ian Schofield

Italy’s Little-Known Early Access Program

Italy’s early access system is mainly used for unapproved uses of authorized medicines, and is driven by clinicians, rather than companies.

Reimbursement Italy

Biosimilar Interchangeability Policies Need Closer Alignment

Regulators should take more of a role in decisions on biosimilar switching and substitution, and international interchangeability practices should be brought into line, delegates at Medicines for Europe’s recent biosimilars conference heard.

International Biosimilars

Further Brexit Delay Avoids No-Deal Impact For Pharma – For Now

The EU has given the UK another extension, this time until 31 October, to find a solution to the Brexit impasse. In the meantime, things will stay pretty much as they are for the life sciences sector, although the possibility of a no-deal exit remains if a withdrawal agreement cannot be ratified. 
Brexit Regulation

Industry Survey Lays Bare Huge Disparities In Access To New Drugs In Europe

A new survey has shown wide differences in patient access to new medicines across, and even within, European countries, with time to access after drug approval ranging from 100 to 1,000 days. Industry has put the blame on factors such as duplicative clinical assessments, the length of HTA processes, and local formulary decisions.

Market Access Europe

Leadiant Hit By Second Complaint Over Price Of CTX Drug In Europe

A second complaint has been filed, this time in Belgium, over the “excessive” price hike on Leadiant’s CDCA-containing drug for the rare genetic disorder, CTX.

Belgium Netherlands

Biosimilar Makers Take On ‘Huge’ Barriers To A Sustainable European Market

The biosimilars industry in Europe will face a struggle over the next few years as the longer-term sustainability of the market is threatened by a dearth of big biologic patent expiries and a growing number of new innovative drugs targeted at smaller patient populations. The Pink Sheet spoke to Adrian van den Hoven and Marc-Alexander Mahl of the generics and biosimilar medicines association, Medicines for Europe, about the sector’s key challenges and how they can be tackled.

Biosimilars Europe
See All